Thomas Newell Chase
#126,757
Most Influential Person Now
Thomas Newell Chase's AcademicInfluence.com Rankings
Thomas Newell Chasepsychology Degrees
Psychology
#2638
World Rank
#3046
Historical Rank
Neuropsychology
#67
World Rank
#70
Historical Rank
Download Badge
Psychology
Thomas Newell Chase's Degrees
- PhD Clinical Psychology University of California, San Diego
Why Is Thomas Newell Chase Influential?
(Suggest an Edit or Addition)Thomas Newell Chase's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. (1998) (1784)
- Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease (1998) (495)
- GABA in nervous system function (1976) (493)
- Alzheimer's disease (1983) (456)
- Dopaminergic modulation of cortical function in patients with Parkinson's disease (2002) (415)
- Cortical abnormalities in Alzheimer's disease (1984) (395)
- Degradation of α-Synuclein by Proteasome* (1999) (380)
- Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, part II (1988) (337)
- Levodopa‐induced dyskinesias improved by a glutamate antagonist in parkinsonia monkeys (1996) (310)
- Adenosine A2A receptor antagonist treatment of Parkinson’s disease (2003) (299)
- Dopamine Modulates the Response of the Human Amygdala: A Study in Parkinson's Disease (2002) (297)
- Towards a behavioral typology of Alzheimer's patients. (1986) (247)
- Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease (1990) (243)
- Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. (1999) (235)
- On‐off response (1975) (232)
- Dopaminergic effects on simple and choice reaction time performance in Parkinson's disease (1988) (223)
- Coexistence of neuropeptide Y and somatostatin in rat and human cortical and rat hypothalamic neurons (1984) (207)
- AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys (2000) (203)
- Regional cortical dysfunction in Alzheimer's disease as determined by positron emission tomography (1984) (203)
- Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease (1987) (195)
- Differential perceptual-spatial impairment in Huntington's and Alzheimer's dementias. (1984) (184)
- Semantic fluency in Alzheimer's, Parkinson's, and Huntington's disease : dissociation of storage and retrieval failures (1993) (176)
- Wearing‐off fluctuations in Parkinson's disease: Contribution of postsynaptic mechanisms (1994) (174)
- The Functional Neuroanatomy of Tourette's Syndrome: An FDG-PET Study. I. Regional Changes in Cerebral Glucose Metabolism Differentiating Patients and Controls (1993) (171)
- Pathogenesis of dyskinesias in parkinson's disease (1989) (167)
- Effects of serotonin 5‐HT1A agonist in advanced Parkinson's disease (2005) (164)
- Rationale for continuous dopaminomimetic therapy of Parkinson's disease. (1989) (160)
- Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, Part I (1988) (158)
- Intravenous amantadine improves levadopa‐induced dyskinesias: An acute double‐blind placebo‐controlled study (2001) (156)
- Motor fluctuations in Parkinson's disease: Pathogenetic and therapeutic studies (1987) (147)
- Huntington’s disease: A randomized, controlled trial using the NMDA-antagonist amantadine (2002) (143)
- Levodopa therapy (1998) (141)
- Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. (2003) (137)
- Wechsler Adult Intelligence Scale performance. Cortical localization by fluorodeoxyglucose F 18-positron emission tomography. (1984) (137)
- Apathy in Neuropsychiatric Disease: Diagnosis, Pathophysiology, and Treatment (2011) (132)
- Tissue transglutaminase catalyzes the formation of alpha‐synuclein crosslinks in Parkinson's disease (2004) (131)
- Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates (2005) (130)
- Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease (1998) (130)
- Neostriatal mechanisms in Parkinson's disease (1998) (129)
- Motor response complications and the function of striatal efferent systems (1993) (126)
- Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease. (1991) (118)
- Short-term effects of high-dose 17β-estradiol in postmenopausal PD patients (1999) (116)
- Clinical and electroencephalographic manifestations of vascular lesions of the pons (1968) (115)
- Huntington's disease (1976) (109)
- Catechol‐O‐methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients (1993) (109)
- Central monoamines and hyperkinesis of childhood (1976) (106)
- Frontal lobe function in progressive supranuclear palsy. (1990) (105)
- Continuous Transdermal Dopaminergic Stimulation in Advanced Parkinson's Disease (2001) (98)
- Mesocortical Dopaminergic Function and Human Cognition (1988) (96)
- Structural and functional studies of Gilles de la Tourette syndrome. (1986) (94)
- The Functional Neuroanatomy of Tourette's Syndrome: An FDG-PET Study. II: Relationships between Regional Cerebral Metabolism and Associated Behavioral and Cognitive Features of the Illness (1995) (93)
- Pathophysiology of motor response complications in Parkinson's disease: Hypotheses on the why, where, and what (2000) (91)
- Alzheimer's disease (1987) (88)
- The Functional Neuroanatomy of Tourette's Syndrome: An FDG PET Study III: Functional Coupling of Regional Cerebral Metabolic Rates (2002) (87)
- Translating A2A antagonist KW6002 from animal models to parkinsonian patients (2003) (87)
- Functional neuroanatomy of Tourette syndrome. Limbic-motor interactions studied with FDG PET. (1992) (86)
- Heterogeneity in Alzheimer's disease: progression rate segregated by distinct neuropsychological and cerebral metabolic profiles. (1992) (86)
- Selective deficits in cognition and memory in high-functioning parkinsonian patients. (1990) (84)
- Effects of the Full Dopamine Dl Receptor Agonist Dihydrexidine in Parkinson's Disease (1998) (81)
- CFS hydroxylase cofactor levels in some neurological diseases. (1980) (81)
- Visuospatial cognition in Huntington's disease (1991) (81)
- Muscarinic agonist therapy of Alzheimer's disease. A clinical trial of RS-86. (1986) (81)
- No response to high‐dose muscarinic agonist therapy in Alzheimer's disease (1988) (80)
- Cerebrospinal fluid monoamine catabolites in drug-induced extrapyramidal disorders. (1970) (80)
- Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease. (1994) (76)
- Cerebral mapping of apraxia in Alzheimer's disease by positron emission tomography (1986) (75)
- The limbic-hypothalamic-pituitary-adrenal axis in Huntington's disease (1991) (75)
- Quetiapine Attenuates Levodopa-Induced Motor Complications in Rodent and Primate Parkinsonian Models (2002) (75)
- A trial of dextromethorphan in parkinsonian patients with motor response complications (1998) (75)
- Apomorphine responses in parkinson's disease and the pathogenesis of motor complications (1997) (74)
- Substance P in human cerebrospinal fluid (1980) (74)
- Effect of L-Dopa on the Sleep of Man (1970) (72)
- Magnetic resonance imaging in Huntington disease. (1986) (70)
- Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. (1996) (70)
- Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease (1992) (68)
- Cognitive concomitants of dopamine system stimulation in parkinsonian patients. (1987) (66)
- Effect of L-DOPA on depression. (1969) (64)
- Cortical and subcortical chemical pathology in Alzheimer's disease as assessed by multislice proton magnetic resonance spectroscopic imaging (1996) (62)
- Renaissance of amantadine in the treatment of Parkinson's disease. (2003) (62)
- Buspirone, Parkinson's disease, and the locus ceruleus. (1986) (62)
- Hypothalamic releasing factors and Parkinson disease. (1974) (61)
- Acute pharmacologic blockade of dyskinesias in Parkinson's disease (1996) (61)
- Huntington's disease. (1975) (60)
- Parkinson's disease (1972) (59)
- The Significance of Continuous Dopaminergic Stimulation in the Treatment of Parkinson’s Disease (2012) (59)
- Transdermal dopaminergic D2 receptor agonist therapy in Parkinson's disease with N‐0923 TDS: A double‐blind, placebo‐controlled study (2001) (59)
- Relation of EEG alpha background to parietal lobe function in Alzheimer's disease as measured by positron emission tomography and psychometry (1988) (59)
- Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemi-parkinsonian rat (1997) (58)
- Effect of L‐dopa alone and in combination with an extracerebral decarboxylase inhibitor on blood pressure and some cardiovascular reflexes (1970) (54)
- Memory impairment in patients with progressive supranuclear palsy. (1989) (54)
- Effect of an opiate antagonist on movement disorders. (1978) (54)
- Central monoamine metabolism in Parkinson's disease. (1972) (54)
- Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy (1994) (54)
- A randomized, controlled trial of remacemide for motor fluctuations in Parkinson’s disease (2001) (54)
- Dietary influences on the antiparkinsonian response to levodopa. (1987) (52)
- Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease (2005) (52)
- Spinal fluid CRF reduction in Alzheimer's disease (1986) (52)
- Central mechanisms and levodopa response fluctuations in Parkinson's disease. (1988) (51)
- Striatal plasticity and extrapyramidal motor dysfunction. (2004) (51)
- D‐Cycloserine Treatment of Alzheimer Disease (1994) (50)
- Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease. (2003) (49)
- Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa (1994) (49)
- Distinct Pathological Features of the Gallyas‐ and Tau‐positive Glia in the Parkinsonism‐Dementia Complex and Amyotrophic Lateral Sclerosis of Guam (1997) (48)
- Caffeine and the antiparkinsonian response to levodopa or piribedil (1975) (47)
- Amyotrophic lateral sclerosis of Guam: the nature of the neuropathological findings (2004) (47)
- A comparison of FDG PET and IQNB SPECT in normal subjects and in patients with dementia. (1992) (46)
- Selective Deficits in Alzheimer and Parkinsonian Dementia: Visuospatial Function (1990) (46)
- Physostigmine treatment of progressive supranuclear palsy (1989) (45)
- Parkinson disease treated with a suspected dopamine receptor agonist. (1974) (45)
- Gilles de la tourette syndrome: Studies with the fluorine‐18‐labeled fluorodeoxyglucose positron emission tomographic method (1984) (45)
- Cortical glucose utilization patterns in primary degenerative dementias of the anterior and posterior type. (1987) (45)
- Impairment of central auditory function in Alzheimer's disease. (1990) (44)
- GABA-agonist therapy for Alzheimer's disease. (1986) (44)
- Clonidine treatment of Alzheimer's disease. (1989) (44)
- Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease (1997) (44)
- [3H]MK-801 binding in Alzheimer's disease (1988) (43)
- Drug-induced extrapyramidal disorders. (1972) (43)
- Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease (1992) (43)
- Controlled trial of propranolol in intermittent claudication (1975) (43)
- Lysine vasopressin in Alzheimer disease (1982) (42)
- Levodopa methyl ester treatment of Parkinson's disease (1987) (42)
- Dopamine and memory function in Parkinson's disease (1989) (41)
- No evidence for altered muscle mitochondrial function in Parkinson's disease. (1993) (41)
- Treatment of Huntington disease with a cholinergic agonist (1978) (41)
- Levodopa-induced dyskinesias. Comparison in Parkinsonism-dementia and amyotrophic lateral sclerosis. (1973) (41)
- Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease (2004) (39)
- Tourette syndrome. Extending basic research to clinical care. (1992) (39)
- Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging (1992) (38)
- Effect of probenecid on free 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) and its sulphate in human cerebrospinal fluid. (1973) (38)
- Selective D-1 dopamine receptor agonist treatment of parkinson's disease (2005) (38)
- Risk factors for motor response complications in L-dopa-treated parkinsonian patients. (1993) (37)
- Serotonergic mechanisms in Parkinson's disease. (1972) (37)
- Partial dopamine agonist therapy of levodopa‐induced dyskinesias (1992) (36)
- THIP treatment of Huntington's disease (1983) (36)
- Levodopa peak response time reflects severity of dopamine neuron loss in Parkinson's disease (1994) (36)
- Intravenous administration of L-kynurenine to rhesus monkeys: Effect on quinolinate and kynurenate levels in serum and cerebrospinal fluid (1993) (36)
- 3–0‐methyldopa and motor fluctuations in Parkinson's disease (1987) (36)
- Peripheral beta‐adrenergic blockade treatment of parkinsonian tremor (1984) (35)
- Adenosine 3',5'-monophosphate in cerebrospinal fluid. Effect of drugs and neurologic disease. (1973) (34)
- Diffuse involvement in progressive aphasia (1983) (34)
- Depressed monoamine catabolite levels in cerebrospinal fluid of patients with parkinsonism dementia of Guam. (1970) (34)
- ALZHEIMER'S DISEASE AND THE PARIETAL LOBE (1983) (33)
- Inhibition of fast axoplasmic transport by acrylamide. (1978) (32)
- Glutamate release inhibition ineffective in Levodopa‐induced motor complications (2006) (32)
- Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism (1970) (31)
- Biochemical and pharmacologic studies of dystonia (1970) (31)
- Modification by L-dopa of a case of progressive supranuclear palsy. With evidence of defective cerebral dopamine metabolism. (1970) (31)
- 5-hydroxytryptophan in parkinsonism. (1970) (30)
- Huntington's disease (1986) (30)
- Neuropsychological and Glucose Metabolic Profiles in Asymmetric Parkinson’s Disease (1992) (29)
- Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study. (2001) (29)
- Neurochemical Alterations in Parkinson's Disease (1980) (29)
- Amyotrophic lateral sclerosis. A study of central monoamine metabolism and therapeutic trial of levodopa. (1971) (29)
- Demonstration of CSF gamma‐globulin banding in presenile dementia (1980) (29)
- Guanfacine treatment of Alzheimer's disease. (1989) (28)
- Controlled release levodopa treatment of motor fluctuations in Parkinson's disease. (1987) (28)
- Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer’s Disease (2017) (27)
- The cerebral syndromes associated with dissecting aneurysm of the aorta. A clinicopathological study. (1968) (27)
- No changes in central quinolinic acid levels in Alzheimer's disease (1989) (26)
- Tourette syndrome: genetics, neurobiology, and treatment. (1992) (26)
- Mapping of Rat Brain Using the Synuclein‐1 Monoclonal Antibody Reveals Somatodendritic Expression of α‐Synuclein in Populations of Neurons Homologous to those Vulnerable to Lewy Body Formation in Human Synucleopathies (2003) (26)
- Opioid peptides in Parkinson's disease: effects of dopamine repletion (1991) (26)
- Fluctuation in response to chronic levodopa therapy: pathogenetic and therapeutic considerations. (1987) (26)
- Treatment with tryptophan of levodopa-associated psychiatric disturbances. (1980) (26)
- Controlled release levodopa-carbidopa (CR-5) in the management of parkinsonian motor fluctuations. (1987) (25)
- Changes in cerebral glucose metabolism with normal aging (1997) (25)
- Reduced brain somatostatin levels in Alzheimer's disease. (1985) (25)
- Metabolic effects of scopolamine and physostigmine in human brain measured by positron emission tomography (1994) (25)
- Glutamatergic therapy of Huntington's chorea. (1992) (25)
- Exercise and the Antiparkinsonian Response to Levodopa (1987) (25)
- Central monoamine metabolism in man. Effect of putative dopamine receptor agonists and antagonists. (1973) (25)
- A gene for Parkinson disease. (1997) (24)
- FLUCTUATING LEVODOPA CONCENTRATIONS AND PARKINSON'S DISEASE (1985) (24)
- Dopaminergic mechanisms in patients with extrapyramidal disease. (1975) (24)
- Implicit memory in Alzheimer's disease. (1995) (24)
- RAPIDLY PROGRESSIVE ALZHEIMER'S DISEASE (1989) (23)
- Somatostatin replacement therapy for alzheimer dementia (1991) (23)
- Striatal dopaminoceptive system changes and motor response complications in L-dopa-treated patients with advanced Parkinson's disease. (1993) (23)
- Cholecystokinin and neurotensin gradients in human CSF. (1985) (22)
- ‘On—off’ effects: the new challenge in parkinsonism (1983) (22)
- Catecholamines and indoleamines in patients with Duchenne muscular dystrophy. (1972) (22)
- Cerebral muscarinic receptors in primary degenerative dementia as evaluated by SPECT with iodine-123-labeled QNB. (1990) (22)
- End‐of‐dose dystonia in Parkinson's disease (1993) (21)
- Clonidine and the anti-parkinsonian response to l-dopa or piribedil (1976) (21)
- HUNTINGTON'S CHOREA TREATED WITH LITHIUM CARBONATE (1974) (21)
- Sustained-release levodopa. (1973) (20)
- Clinical trials in dementia: learning effects with repeated testing. (1991) (20)
- Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine. (1991) (20)
- Inhibition of drug metabolism by levodopa in combination with a dopa-decarboxylase inhibitor. (1971) (19)
- Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders. (1989) (18)
- Parkinson's disease: Neurodegenerative mechanisms and neuroprotective interventions—report of a workshop (1998) (18)
- Long-lasting dyskinesia induced by levodopa. (1971) (18)
- Assessment of intellectual function in dementing disorders: validity of WAIS-R short forms for patients with Alzheimer's, Huntington's, and Parkinson's disease. (1993) (18)
- Fenfluramine in man: hypophagia associated with diminished serotonin turnover. (1975) (18)
- The neostriatum and nucleus accumbens in parkinsonism-dementia complex of Guam: a pathological comparison with Alzheimer's disease and progressive supranuclear palsy (2004) (17)
- Topographic investigation of brain atrophy in parkinsonism-dementia complex of Guam: a comparison with Alzheimer's disease and progressive supranuclear palsy. (1994) (17)
- Milacemide therapy for Parkinson's disease (1993) (16)
- Gene Therapy for Parkinson's Disease: An Approach to the Prevention or Palliation of Levodopa-Associated Motor Complications (1997) (16)
- Plasma growth hormone and prolactin response to dopaminergic GABAmimetic and cholinergic stimulation in Huntington's disease (1983) (16)
- Changed distribution pattern of the constitutive rather than the inducible HSP70 chaperone in neuromelanin‐containing neurones of the Parkinsonian midbrain (2006) (15)
- Dynorphin agonist therapy of Parkinson's disease. (1993) (15)
- Cerebral metabolic changes in Alzheimer's disease: neurobehavioral patterns. (1996) (14)
- Treatment of parkinson's disease with the partial dopamine agonist EMD 49980 (1993) (14)
- Biochemical aids in the diagnosis of Parkinson's disease. (1976) (14)
- Pathogenetic studies of motor fluctuations in Parkinson's disease. (1988) (14)
- Fusaric acid in Parkinson's disease (1974) (14)
- Personality variables, neurological and psychopathological symptoms in patients suffering from spasmodic torticollis. (1988) (14)
- Motor effects of the partial dopamine agonist (−)‐3‐(3‐hydroxyphenyl)‐N‐n‐propylpiperidine (preclamol) in Parkinson's disease (1994) (13)
- Fenfluramine hydrochloride treatment of parkinsonism. (1977) (13)
- Catecholamine metabolism and neurologic disease (1974) (12)
- Endocrinologic regulation of carbohydrate metabolism. Amyotrophic lateral sclerosis and Parkinsonism-dementia on Guam. (1979) (12)
- M.I.F.: effect on levodopa dyskinesias in man. (1973) (11)
- Motor response complications with chronic levodopa therapy. (1990) (11)
- Dystonia: treatment with bromocriptine. (1985) (11)
- Cerebral Metabolic Rate of Glucose and Alzheimer's Disease (1986) (11)
- Mitochondrial function in Parkinson's disease (1992) (11)
- Central monoamines and hyperkinase of childhood. (1976) (10)
- Amyotrophic lateral sclerosis: metabolism of central monoamines and treatment with L-dopa. (1971) (10)
- Letter: Huntington's disease: treatment with imidazole-4-acetic acid. (1975) (10)
- Behavioural and biochemical effects of fenfluramine in patients with neurologic disease. (1975) (9)
- Probenecid test in Parkinson's disease. (1971) (9)
- Parkinsonism‐dementia of Guam (1971) (9)
- Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease. (1991) (9)
- Dopamine D-1 receptor agonist stimulation of prolactin secretion in man (1988) (9)
- Metabolic studies with bromocriptine in patients with idiopathic parkinsonism and Huntington's chorea. (1976) (8)
- Serotonergic mechanisms and extrapyramidal function in man. (1974) (8)
- 3-O-methyldopa and motor fluctuations in Parkinson's disease. (1987) (7)
- Methyldopa or methyldopahydrazine as levodopa synergists. (1973) (7)
- Subgroups in Alzheimer's disease: fact or fiction? (1990) (7)
- Dopamine-receptor subtype-selective agonists in the treatment of Parkinson's disease (1995) (7)
- L-Dopa and the treatment of extrapyramidal disease. (1975) (7)
- CSF galanin and neuropeptide Y immunoreactivity in progressive supranuclear palsy (1992) (6)
- Modification of cerebral ischemic damage by anesthetics. (1978) (6)
- Serotonergic functions in man. (1976) (5)
- Current and Future Therapeutic Approaches (2005) (4)
- Serotonergic-dopaminergic interactions and extrapyramidal function. (1974) (4)
- Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease (1996) (4)
- Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications (1998) (4)
- Limbic system dysfunction in Alzheimer's disease. (1995) (4)
- Amantadine for Levodopa-Induced Dyskinesias (2016) (4)
- Parkinsonism‐dementia of Guam (1974) (4)
- A unique protein in normal human cerebrospinal fluid. (1983) (4)
- Cognitive and cerebral metabolic function in early and advanced Alzheimer's disease. (1984) (4)
- Differential classification of dementia. (1995) (3)
- Treatment of Huntington disease with a direct cholinergic agonist (1978) (3)
- Treatment strategies in primary degenerative dementias (1991) (3)
- Treatment of resting tremor by beta-adrenergic blockade. (1984) (3)
- Vasopressin in Alzheimer's disease (1983) (3)
- Quantification of Dopaminomimetic Effects on Parkinsonian Symptoms Using Automatic and Voluntary Postural Responses (1995) (3)
- Motor response complications in advanced Parkinson's disease. (1988) (3)
- Letter: Huntington's chorea treated with lithium carbonate. (1974) (2)
- Acute motor responses to intravenous levodopa in Parkinsonian patients (1992) (2)
- Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism. (1970) (2)
- Suprathreshold levodopa doses, dyskinesias, and disability in advanced Parkinson's disease (1998) (2)
- Square‐wave action dystonia in Parkinson's disease (1998) (2)
- Clinical studies of dopaminergic mechanisms. (1974) (2)
- High-dose cholinesterase inhibitor treatment of Alzheimer’s disease (2015) (2)
- Rational approaches to the pharmacotherapy of chorea. (1976) (2)
- EMD 23,448: Effects of a putative dopamine autoreceptor agonist in chorea (2005) (1)
- Erratum: Dopamine modulates the response of the human amygdala: A study in Parkinson's disease (Journal of Neuroscience (October 15, 2002) (9099-9103)) (2002) (1)
- Chapter 3: Pharmacology of Dystonia (1977) (1)
- STRIATAL GLUTAMATERGIC DYSFUNCTION AND EXTRAPYRAMIDAL MOTOR BEHAVIOR (1996) (1)
- The effects of clinical manifestations in Parkinson's disease on standing balance (1992) (1)
- [Spasmodic torticollis. A study of symptoms, course, family history and psychopathology]. (1986) (1)
- Heterogeneity inAlzheimer's disease: progression ratesegregated bydistinct neuropsychological andcerebral metabolic profiles (1992) (1)
- Failure of buspirone and verapamil to improve spasmodic torticollis. (1992) (1)
- Reply (1989) (1)
- The Pharmacotherapy of Parkinson's Disease: Current Status and Future Opportunities (1994) (1)
- Cerebrospinal fluid (CSF) neurotransmitters in the stiff man syndrome (1979) (1)
- Duration of Illness and Response to Tryptophan in Parkinson's Disease-Reply (1980) (1)
- high-functioning parkinsonian patients . Selective deficits in cognition and memory in (1)
- Frontiers in catecholamine researchCatecholamine metabolism in neurologic disease (1973) (1)
- Levodopa in Parkinsonism (2012) (1)
- A2A antagonists for PD (2003) (0)
- Comparison oftheclinical pharmacology of (- )NPAandlevodopa inParkinson's disease (2011) (0)
- [Effect of L-dopa on clinical duration and quality of life of patients with Parkinsonism-dementia in Guam]. (1983) (0)
- The Clinical neurosciences (1975) (0)
- HIGH DOSE DONEPEZIL WITH SOLIFENACIN (CPC-201) IMPROVES SAFETY AND INITIAL EFFICACY IN ALZHEIMER’S DISEASE (2016) (0)
- Abstracts from ASENT 2004 Annual Meeting March 11–13, 2004 (2004) (0)
- Cognitive Corollaries of Dopaminomimetic Therapy of Parkinson's Disease (1987) (0)
- Alzheimer ' s disease . in demented patients with Parkinson ' s and Differential memory and executive functions (0)
- D 1 dopamine receptor agonist treatment of parkinsons disease (1986) (0)
- Questions raised on monoamines in childhood hyperkinesis (1977) (0)
- J. Stephen Fink, MD, PhD (1950–2002) (2003) (0)
- The use and composition for the treatment of dementia (2009) (0)
- Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer’s Disease (2017) (0)
- Dietary Influences on Motor Fluctuations in Parkinson's Disease (1987) (0)
- Dopamine agonist therapy of naturally occurring and drug-induced hyperkinetic extrapyramidal disorders (1979) (0)
- [Abnormal carbohydrate metabolism in amyotrophic lateral sclerosis and parkinsonism-dementia complex on Guam (author's transl)]. (1978) (0)
- [Changes in the nigrostriatal dopamine receptor compartment after continuous dopaminergic infusions in Parkinson disease]. (1991) (0)
- Clinical perspectives in neuropeptides in the central nervous system (1989) (0)
- Use of brain imaging in animals as a component of drug discovery (1992) (0)
- CENTRAL CATECHOLAMINES AND NEUROLOGIC DISEASE (1979) (0)
- Current and Future Therapeutic Approaches 473 473 (2004) (0)
- Proceedings: Clinical studies of dopaminergic mechanisms. (1974) (0)
- Dopaminergic modulation of the neocortical network that subserves facial affect recognition: A study in patients with Parkinson's disease (2001) (0)
- Abstracts from ASENT 2004 Annual Meeting March 11–13, 2004 (2004) (0)
- Abstracts from the ASENT 2005 Annual Meeting March 3–5, 2005 (2005) (0)
- function in Parkinson ' s disease . No evidence for altered muscle mitochondrial (0)
- Fenfluramine and Parkinson's Disease-Reply (1977) (0)
This paper list is powered by the following services:
